Left ventricular remodeling (LVR) after myocardial infarction is associated with an increased risk of heart failure and death. In spite of a modern therapeutic approach, LVR remains relatively frequent and difficult to predict in clinical practice. Our aim was to identify new biomarkers of LVR and understand their involvement in its development.
C
hronic heart failure (HF) remains a major public health problem 1 with a high rate of mortality in spite of recent therapeutic improvements. 2 The most common cause of HF is coronary artery disease and particularly myocardial infarction (MI). 3 Left ventricular remodeling (LVR) after MI is a dynamic and complex process that occurs in response to myocardial damage and is associated with an increased risk of HF and cardiovascular death. 4, 5 Post-MI LVR can be divided into 2 phases. The early phase (occurring few hours to several weeks after MI onset) involves the expansion of the infarct zone, including dilatation and thinning of the infarct zone. 6 The late phase (months, years) involves globally the LV and is associated with time-dependent dilatation, distortion of ventricular shape, mural hypertrophy, and structural tissue changes. 7 Although LVR may be considered as a protective mechanism to maintain systolic flow and cardiac pump function, this phenomenon leads to alterations of global LV function and ultimately aggravates HF. In 2 independent prospective echocardiographic studies (REVE and REVE-2 [Remodelage Ventriculaire]), we observed a 30% to 40% LVR rate after a first acute anterior wall MI despite high acute reperfusion rates and widespread prescription of secondary prevention medications. 8, 9 However, LVR remains difficult to predict in clinical practice and its severity cannot be fully predicted based on its known determinants such as those related to infarct size, anterior infarct location, or LV ejection fraction. 10 Circulating biological markers called biomarkers may facilitate the diagnosis and the prognosis of LVR and HF. 11 The only biomarker clinically used in MI patients is BNP (B-type natriuretic peptide) whose concentration helps to predict the risk of HF, 12 but data on its ability to predict LVR are discordant. 9, [13] [14] [15] CLU (clusterin) is constitutively expressed in most mammalian tissues and is highly conserved across species. Several functions have been proposed for CLU such as complement activity regulation, lipid transport, apoptosis regulation, and cell interaction. 16 Several studies show increased CLU levels in plasma 17, 18 and LV 18, 19 of MI patients at early stage after MI. Until now, the relationship of plasma CLU levels with LVR post-MI has not been studied despite a recent study showing that CLU is independently associated with chronic HF. 20 In this study, we show for the first time that (1) CLU is increased in late stage after MI and is associated with LVR; (2) CLU expression and secretion are increased by hypertrophied cardiomyocytes and seem play a prohypertrophic role; and (3) plasma levels of CLU are predictor of early death in HF patients.
MATERIALS AND METHODS
Detailed information is supplied in the Data Supplement. The data, analytic methods, and study materials will be made available to other researchers upon request for purposes of reproducing the results or replicating the procedure.
Patients
The studies were approved by the Ethics Committee of the Centre Hospitalier et Universitaire de Lille and comply with the Declaration of Helsinki. All patients gave written informed consent.
REVE-2 Study
The design of the REVE-2 study has been published in detail elsewhere. 9 We enrolled 246 patients with a first anterior wall Q-wave MI between February 2006 and September 2008. The protocol required serial echographic studies at baseline (days 3 to 7) and 3 and 12 months after MI. LVR was defined as percent change in end diastolic volume from baseline to 1 year. Serial blood samples were taken at discharge (days 3 to 7) and 1, 3, and 12 months after MI.
INCA Study (Insuffisant Cardiaque)
All patients referred for evaluation of systolic HF (LVEF <45%) in our institution between November 1998 and May 2010 were included in a prospective cohort on prognostic indicators. 5, 21, 22 From this population, we selected 198 patients included between November 1998 and December 2005, as previously described. 23 Blood sample was obtained at inclusion.
WHAT IS NEW?
• This is the first study analyzing the relationship of plasma CLU (clusterin) levels with left ventricular remodeling after myocardial infarction (MI), discovered by proteomic analysis.
• Our findings suggest that CLU is involved in compensatory hypertrophy and plays a role in the early and late phases after MI.
• Modulation of plasma CLU levels has, in part, a cardiac origin after hypertrophy of cardiomyocytes.
• We show a prohypertrophic role of CLU via ERK (extracellular signal-regulated kinase) 1/2 pathway in cardiomyocyte under β-adrenergic stress.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Despite modern therapeutic approaches, left ventricular remodeling after MI remains relatively frequent and difficult to predict in clinical practice.
• CLU plasma levels are associated with left ventricular remodeling development after MI.
• CLU plasma levels are a new predictive marker of early cardiac mortality in heart failure patients with reduced ejection fraction.
• A significant increase of intracellular CLU was found in failing human hearts.
Human Heart Biopsies
Tissues from failing and nonfailing human hearts were obtained, respectively, from Lille University Hospital (France) and from Catholic University of Leuven (Belgium).
Animal Models
All animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication NO1-OD-4-2-139, revised in 2011). MI was induced in 10-week-old male Wistar rats (Janvier, Le Genest St Isle, France) by ligation of the left anterior descending coronary artery. 24, 25 Sham-operated and MI rats were then further separated into 2 subgroups that were euthanized at 7 days (n=8 per group) or 2 months (n=9-11 per group) post-MI. Hemodynamic and echocardiographic measurements were taken 2 months after surgery, followed by heart excision, as previously described.
26,27

Cellular Models
H9c2 cells and primary cultures of neonate rat cardiomyocytes (NCM) were prepared and cultured as previously described.
28
Proteomic Analysis of Plasma Samples From REVE-2 Patients
Plasma samples underwent no more than 2 freeze/thaw cycles and were treated using combinatorial peptide ligand library method to allow for the enrichment in medium-and low-abundance proteins. 29 Two-dimensional differential gel electrophoresis was performed and analyzed as previously described. 30 Differentially regulated spots were excised manually from a preparative gel performed with 500 μg of proteins and in-gel digested with trypsin.
31
Western Blot Analysis
The primary antibodies and dilution used for Western blot analysis are detailed in the Table I 
RESULTS
CLU Is Increased in Patients With High LVR After MI
We performed differential proteomic analysis of 10 pools comprising 5 patients from the REVE-2 study, 9 the pools (1-5) and (37) (38) (39) (40) (41) corresponding, respectively, to the lowest (−17.0±6.2%) and the highest (+37.2±13%) LVR ( Figure 1A ). Because inflammatory response and cytokines are particularly active in early phase after MI, we selected, for each patient pool, the plasma samples collected at 3 months post-MI for the differential 2D-differential gel electrophoresis-based proteomic analysis. We found 7 spots differentially expressed (P<0.05) between low and high LVR pooled patients. The MS analyses identified 3 spots as being CLU ( Figure 1B ). Detailed 2D spots corresponding to CLU are presented for each pool of plasma analyzed (5 for no LVR and 5 for high LVR groups; Figure I in the Data Supplement; Table  III in the Data Supplement). We observed that the spots 842, 853, and 873 identified as being CLU gathered as a cluster in this gel within a range of molecular weight (37-45 kDa) and of isoelectric point (4.7-5.0).
To confirm these results, we analyzed CLU plasma levels by 1D Western blotting from individual plasma samples of 45 REVE-2 patients at 3 months post-MI. Patients were divided by tertile of Δend diastolic volume with mean Δend diastolic volume of −7.4% (−13.9% to 1%) for tertile 1, 11.0% (5.3%-14%) for T2, and 22.6% (18.7%-29.5%) for T3. We observed in crude plasma one band with a molecular mass of 36 kDa corresponding to s-CLU (secreted form of CLU) that is significantly increased in plasma of patients with LVR (P<0.01; Figure 1C ). We also identified CLU as being significantly increased in plasma from patients with LVR at 1 year post-MI ( Figure II in the Data Supplement).
CLU Is Increased in the LV of Rats After MI and Correlated Positively With LVR
To determine if increased plasma CLU levels has a cardiac origin, we analyzed CLU expression in the LV of rats at 7 days and 2 months post-MI. In this model, cardiac remodeling was characterized by LV dilatation as shown by significantly increased LV end-diastolic and end-systolic diameters in the 2 months post-MI rats (Table IV in the Data Supplement). Cardiac hypertrophy was also increased in post-MI: LV weight/body weight and heart weight/body weight ratios were significantly increased (1) (2) (3) (4) (5) and the highest (37-41) percent of LVR were used for the 2D-DIGE analysis after treatment of pooled plasma by the combinatorial peptide ligand library (CPLL) method as previously described.
29 B, Representative 2D-DIGE gel and bioinformatic analysis of spots surrounded corresponding to CLU in pooled plasma of patients with the lowest and highest percent of LVR at 3 months post-myocardial infarction (MI). C, Representative Western blot (left) and quantification (right) s-CLU (secreted form of CLU) in plasma of 45 REVE (Remodelage Ventriculaire)-2 patients at 3 months post-MI. Patients were divided by tertile of Δend diastolic volume (n=15 per tertile), with mean Δend diastolic volume of −7.4% (−13.9% to 1%) for tertile 1 (T1), 11.0% (5.3-14%) for tertile 2 (T2) and 22.6% (18.7-29.5%) for tertile 3 (T3). M is size marker, and S is standard added in each 1-dimension gel performed for normalization between gels. Red ponceau (RP) was used to normalize CLU levels. Data are expressed in arbitrary units (A.U.) and presented as box and whisker plots showing median (line) and min to max (whisker). Statistical significance was determined by Kruskal-Wallis test. **P<0.01. in 2 months post-MI rats (Table IV in the Data Supplement) . Also, mRNA levels of ANP (atrial natriuretic peptide) and BNP genes were significantly increased in the LV of rats at 7 days and 2 months post-MI ( Figure IIIA in the Data Supplement), but only BNP plasma levels were significantly increased at 7 days post-MI (Figure IIIB in the Data Supplement).
We first analyzed CLU mRNA and its intracellular protein levels in the LV of rats after MI (Figure 2A ). Quantitative polymerase chain reaction (qPCR) analy- (Figure 2A, left) . Western blot analysis detected 2 bands with a molecular mass of 60 and 40 kDa corresponding, respectively, to the p-CLU (precursor form of CLU) and the m-CLU (mature form of CLU). The m-CLU was the predominant intraventricular form suggesting that CLU maturation is active in the heart independently of MI ( Figure Figure 2B ). Cardiac p-CLU and m-CLU levels were positively correlated with plasma BNP levels (r=0.69, P=0.004/r=0.59, P=0.018, respectively) at 7 days post-MI ( Figure 2C , left). The cardiac m-CLU levels were positively correlated with LV end-diastolic diameter (r=0.59, P=0.004), LV weight/body weight ratio (r=0.48, P=0.034), and heart weight/body weight ratio (r=0.52, P=0.02; data not shown) at 2 months post-MI ( Figure 2C, right) . These data show that CLU expression is increased in LV after MI and is correlated with cardiac remodeling. However, CLU expression is time dependent after MI, suggesting different mechanisms of CLU regulation and different roles of this protein in cardiac remodeling.
CLU Expression and Secretion Are Increased in Hypertrophied Cardiomyocytes
Chronic activation of the adrenergic system with associated upregulation of the renin-angiotensin-aldosterone system plays a major role in cardiac remodeling after MI. To determine the implication of these mechanisms on CLU secretion, we treated H9c2 cells for 48 To determine the implication of hypertrophy on CLU regulation, we treated primary cultures of NCM by ISO (10 μmol/L) for 72 hours and characterized cell hypertrophy by increased cell surface area ( Figure 3A ) and significant increased expression of ANP and BNP genes ( Figure 3B ). As shown in Figure 3C, Figure 3D ). These data confirm that CLU expression and secretion are increased by hypertrophied cardiomyocytes and suggest that increased CLU in plasma after MI has at least in part a cardiac origin.
CLU Silencing in Cardiomyocytes Inhibits Cell Hypertrophy Induced by Isoproterenol
Because CLU expression and secretion were increased in hypertrophied cardiomyocytes, we studied its role on hypertrophy by silencing it to understand its involvement in cardiac remodeling post-MI. We verified that ISO treatment increased significantly phospho-Akt (Ser473)/total Akt (pAkt/Akt) ratio, phospho-ERK (extracellular signal-regulated kinase) 1/2 (Thr202/Tyr204)/total ERK1/2 (pERK1-2/ERK1-2) ratio as previously described [35] [36] [37] with no significant difference on pGSK-3β (Ser9)/total GSK-3β (pGSK/ GSK) ratio ( Figure IVB Figure 4F ). These results suggest that CLU silencing inhibits isoproterenol-induced hypertrophy by inhibition of ERK1/2 pathway.
CLU Is a Predictive Marker of Cardiac Mortality in HF Patients
Because CLU protein levels were higher in the LV of HF rat model than in control rats, we sought to evaluate whether this was also the case in myocardial tissue of HF patients who underwent heart transplantation. We observed an increased level of p-CLU ( Figure 5A ). Using immunohistochemistry, we also observed an increased CLU staining in failing hearts compared with control hearts with no difference on CLU cellular localization ( Figure 5B ). To evaluate whether the s-CLU may be a predictor of adverse effects in HF patients before heart transplantation, we quantified, by 2 methods (quantitative mass spectrometry and ELISA), s-CLU in plasma of chronic systolic HF patients (99 alive and 99 dead patients) from the INCA study recently described. 23 The baseline characteristics of the patients included were matched on age, sex, HF cause, and diabetes mellitus. There was no significant difference in treatment at inclusion in the study. The patients who died from a cardiovascular cause during the 3-year follow-up showed significantly higher New York Heart Association class, BNP level, creatinine level, and lower peak Vo 2 when compared with patients alive at 3 years. Plasma CLU was increased significantly (73. 6 Figure 5C ), independently of HF cause (not shown).
DISCUSSION
LVR post-MI is associated with an increased risk of HF and death. 38 It remains a frequent event despite the modern therapeutic approach and difficult to predict in clinical practice. For this, we designed the REVE-2 study which included 246 patients after a first anterior MI with serial echocardiography examinations and serial samplings in the first year after MI. 9 Our aim was to identify new biomarkers of LVR post-MI and understand their involvement in this evolutive process.
The development of proteomic analysis techniques makes possible to use new strategies without a priori for the identification of proteins involved in cardiovascular pathologies. 39 To identify new biomarkers of LVR post-MI, we performed a differential proteomic analysis, by 2D-differential gel electrophoresis, 40 on enriched plasma prepared as previously described, 29 obtained from REVE-2 patients with high LVR and patients with no LVR evaluated 1 year after an anterior inaugural MI. We identified several polypeptidic spots corresponding to CLU. The observed molecular mass differences for CLU isoforms in our proteomic study can be explained by the potential N-glycosylation of CLU, consisting of associated complex sugars contributing to 20% to 30% of its molecular weight. 41 We validated our results by Western blot analysis showing that s-CLU isoform with a molecular mass of ≈36 kDa is positively associated with high LVR post-MI.
CLU is constitutively expressed in most mammalian tissues and is induced in many organs where tissue injury or remodeling occurs. CLU levels were shown to be increased in plasma of patients after 24 hours of acute MI 17 and recently described in the exosomes isolated from pericardial fluids collected from MI patients. 18 Our proteomic data are the first study showing that CLU is increased in late stage of MI and is associated with LVR. To verify if increased CLU levels in plasma (s-CLU) of LVR patients has in part a cardiac origin, we first used an experimental MI rat model 24 to analyze the temporal CLU expression in the LV after MI. The proteolytic cleavage of CLU precursor (p-CLU, 60 kDa) generate alpha and beta chain of 40 kDa that are glycosylated and assembled to give the mature form, m-CLU that will be then secreted as s-CLU. Our results show that CLU mRNA and its intracellular levels are increased in noninfarcted LV area of MI rat with the mature form as being predominant, suggesting that LV cells are able to express and secrete CLU into the bloodstream. Our results also show that CLU is increased as early as 7 days after MI and correlated with LVR parameters. This finding suggests an implication of CLU in LVR.
To verify if increased CLU expression in the LV is associated with increased CLU secretion, we induced hypertrophy in NCM, a mechanism observed in the noninfarcted area after MI. The 72-hour isoproterenol treatment increased CLU expression as shown by its mRNA and intracellular levels. Our results are in agree- Figure 4 Continued. For RT-qPCR analysis, GAPDH was used to normalize CLU expression, and the data are expressed in arbitrary units (A.U.). For Western blot analysis, red Ponceau (RP) was used to normalize s-CLU levels, and the data are expressed in fold change relative to si-NT transfected cells. E, Quantification by qPCR of ANP (atrial natriuretic peptide; left) and BNP (B-type natriuretic peptide; right) expression in the NCM cells after CLU silencing (si-Clu 1) compared with si-NT transfected cells (n=17 per group). GAPDH was used to normalize ANP and BNP expression, and data are expressed in arbitrary units (A.U.). F, Representative Western blots (left) and quantification (right) of active form of ERK1/2 (pERK1/ERK1 and pERK2/ERK2) in the NCM after CLU silencing (si-Clu 1) compared with si-NT transfected cells (n=19 per group). Data are expressed in fold change in active proteins levels relative to si-NT transfected cells. All data are presented as box and whisker plots showing median (line) and min to max (whisker). Statistical significance was determined by Wilcoxon-Mann-Whitney test. *P<0.05, **P<0.01, ***P<0.001 vs si-NT transfected cells. ment with a previous study showing increased CLU levels in the LV of mouse after chronic β-adrenergic stimulation. 42 Interestingly, we also observed increased CLU in the culture media of hypertrophied NCM. All these data show that CLU expression and secretion are increased in hypertrophic cardiomyocytes and suggest GAPDH was used to normalize intracellular CLU levels. Graphs show individual and median fold change in CLU levels±interquartile range (IQR; 25%-75%) relative to p-CLU of control. B, Immunostaining of CLU in frozen myocardial sections from nonfailing (control) and HF patients with ischemic cardiomyopathy. Nuclei are stained in blue by hematoxylin. C, Quantification of s-CLU (secreted form of CLU) plasma levels in systolic HF patients alive (n=99) or dead (n=99) within 3 years after the initial prognostic evaluation by quantitative mass spectrometry (left) and ELISA (right). Data are presented as box and whisker plots showing median (line) and min to max (whisker). Statistical significance was determined by Wilcoxon-Mann-Whitney test or and by Wilcoxon-signed rank test. **P<0.01 vs Cont., # that the increased CLU plasma levels in REVE-2 patients with high LVR after MI have, in part, a cardiac origin. The physiological role of CLU is complex depending on CLU isoforms, localization, and cellular types. 43 Several data suggest an antiapoptotic role of CLU in early phase after MI. In ischemia/reperfusion rat model, the administration of CLU for 3 days reduced both infarct size and death of rats. 44 In addition, infusion of CLU after acute MI reduced the cardiomyocyte apoptosis and increased the induction of epithelial mesenchymal transition, angiogenesis, and preservation of myocardial function. 18 In vitro, the addition of CLU in culture media inhibited H9c2 apoptosis induced by ischemic/reperfusion. 45 However, in MI rats, CLU was also detected in peri-infarct zone. 46 These data in addition to our results lead us to study the role of CLU on hypertrophy. In our model, CLU silencing in cardiomyocytes decreased cells size, ANP, and BNP expression associated with decreased ERK1/2 activity suggesting a prohypertrophic role of CLU in LVR via ERK1/2 pathway. This is supported by previous studies showing, in one hand, a decrease of ERK1/2 pathways after CLU silencing in cancer cells 47 and, in another hand, a protective effect of some molecules against hypertrophy via inhibition of ERK1/2 activity. 48 Finally, we validate that CLU expression is also increased in the LV of HF patients who underwent heart transplantation. We evaluated whether the secreted form of CLU may be a predictor of adverse effects in HF patients before heart transplantation, and we showed significant increased CLU levels in HF patients who died from a cardiovascular cause during the 3-year follow-up compared with survivors, and it is not depending on the HF cause. A recent prognostic study showed decreased CLU levels in the plasma of HF patients who died compared with survivors. 20 The discrepancy results observed between the 2 studies can be explained by a different design of the study. In our case, we performed a case-control study and they included consecutive older HF patients hospitalized, with only one third of the patients with altered ejection fraction (<30% versus 100% in our study), a higher female/male ratio, and more HF patients with New York Heart Association classes III and IV versus no class IV patients in our study. A recent study confirmed our data with increased levels of CLU found in circulating extracellular vesicles derived from dilated cardiomyopathy patients compared with controls. 49 As in our study, the patients were relatively young (62.3±11.5 years), mostly men (90%) with reduced ejection fraction (36.1±11.7) and a ratio New York Heart Association II/III (80/20). Our results suggest that CLU is a new predictive marker of early cardiac mortality.
In conclusion, our data show that CLU is increased in noninfarcted LV at late stage of MI in the rat model. CLU expression is time dependent in post-MI suggesting different mechanisms of CLU regulation and different roles of this protein in cardiac remodeling. Our data suggest that CLU is involved in the compensatory hypertrophy but its role in HF is not yet elucidated. Because the role of CLU is complex depending on CLU isoforms, localization, and cellular types, it will be important to study the mechanisms involved in CLU expression, maturation, secretion, and degradation in cardiomyocytes to better understand its regulation and its role in different phase after MI. In addition, our study is the first showing that circulating levels of CLU are associated with LVR post-MI and is a new predictive marker of cardiac mortality in HF patients with reduced EF. To consider CLU as a clinically useful biomarker, it should be validated in other cohorts of patients. Our results were obtained in selected patients: (1) with first anterior MI and substantial residual akinesia at predischarge echocardiography, they may not apply to all post-MI patients; and 2) relatively young HF patients with reduced EF. Finally, a gold standard and accurate measurement of CLU usable at hospital should be developed.
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